Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Dongli Zhang, Jie Li, Yaqi Liang, Tao Li, Ming Ji, Xinmin Liu, Wenxin Li, Pengxiao Chen, Jiamin Zhang, Zhengduo Yang, Lulu Wang* and He Chen*, 
{"title":"Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules","authors":"Dongli Zhang,&nbsp;Jie Li,&nbsp;Yaqi Liang,&nbsp;Tao Li,&nbsp;Ming Ji,&nbsp;Xinmin Liu,&nbsp;Wenxin Li,&nbsp;Pengxiao Chen,&nbsp;Jiamin Zhang,&nbsp;Zhengduo Yang,&nbsp;Lulu Wang* and He Chen*,&nbsp;","doi":"10.1021/acs.jmedchem.5c00379","DOIUrl":null,"url":null,"abstract":"<p >Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, <b>dPDL1-4</b> selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, <b>dPDL1-4</b> demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 12","pages":"12641–12657"},"PeriodicalIF":6.8000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00379","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, dPDL1-4 selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, dPDL1-4 demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.

Abstract Image

细胞外hsp90促进双功能小分子降解细胞外和膜蛋白。
溶酶体靶向嵌合体是通过溶酶体途径降解细胞外蛋白和膜蛋白的一种很有前途的策略,但可用的受体选择仍然有限。在此,我们报告了一种新的策略,利用细胞外热休克蛋白90 (eHSP90)通过双功能小分子促进靶蛋白的溶酶体降解,称为细胞外热休克蛋白90靶向嵌合体(eHSPTACs)。通过将HSP90配体连接到靶蛋白配体上,eHSPTACs有效诱导细胞外Alexa Fluor 488标记的α-DNP抗体和膜程序性细胞死亡配体1 (PD-L1)的内化和随后的溶酶体降解。值得注意的是,dPDL1-4选择性地降解肿瘤细胞中的膜PD-L1,而不是正常细胞,从而提高了肿瘤细胞中eHSP90的表达。此外,在B16F10同基因小鼠模型中,dPDL1-4在体内表现出强大的膜PD-L1降解和显著的肿瘤生长抑制。总之,eHSPTACs为肿瘤选择性降解细胞外蛋白和膜蛋白提供了一个通用平台,提供了一种新的治疗途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信